New combo aims to boost CAR-T success in aggressive lymphoma
NCT ID NCT05757219
First seen Nov 01, 2025 · Last updated Apr 24, 2026 · Updated 22 times
Summary
This study tests whether taking itacitinib pills before CAR-T cell therapy can help people with diffuse large B-cell lymphoma (DLBCL) live longer without their cancer growing. About 27 adults who are already eligible for CAR-T treatment will take itacitinib once daily before their standard CAR-T infusion. The goal is to see if this approach improves progression-free survival at 6 months compared to historical rates.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Moffitt Cancer Center
RECRUITINGTampa, Florida, 33617, United States
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
Conditions
Explore the condition pages connected to this study.